Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction
JACC: Heart Failure · 2023-08 · 11 (8) · 893-900
DOI: 10.1016/j.jchf.2023.03.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Heart Failure, 2023-08. Verfasst von Suzanne V Arnold und 7 weiteren Autor:innen. Beteiligte Einrichtung: Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: s…. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Although studies consistently show that beta-blockers reduce morbidity and mortality in patients with reduced ejection fraction (EF), data are inconsistent in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and suggest potential negative effects in heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: The purpose of this study was to examine the association of beta-blockers with heart failure (HF) hospitalization and death in patients with HF and EF ≥40% METHODS: Beta-blocker use was assessed at first encounter in outpatients ≥65 years of age with HFmrEF and HFpEF in the U.S. PINNACLE Registry (2013-2017). The associations of beta-blockers with HF hospitalization, death, and the composite of HF hospitalization/death were assessed using propensity-score adjusted multivariable Cox regression models, including interactions of EF × beta-blocker use. RESULTS: Among 435,897 patients with HF and EF ≥40% (HFmrEF, n = 75,674; HFpEF = 360,223), 289,377 (66.4%) were using a beta-blocker at first encounter; more commonly in patients with HFmrEF vs HFpEF (77.7% vs 64.0%; P 60%. CONCLUSIONS: In a large, real-world, propensity score-adjusted cohort of older outpatients with HF and EF ≥40%, beta-blocker use was associated with a higher risk of HF hospitalization as EF increased, with potential benefit in patients with HFmrEF and potential risk in patients with higher EF (particularly >60%). Further studies are needed to understand the appropriateness of beta-blocker use in patients with HFpEF in the absence of compelling indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: sarnold@saint-lukes.org.
- Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Division of Cardiology, Department of Medicine, Ralph H. Johnson Veterans Administration Medical Cen…
- Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
- Lillehei Heart Institute, Department of Medicine, University of Minnesota College of Medicine, Minneapolis, Minnesota, USA.
Zitieren
APA
Arnold, S. V., Silverman, D. N., Gosch, K., Nassif, M. E., Infeld, M., Litwin, S., Meyer, M., & Fendler, T. J. (2023). Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 11(8), 893-900. https://doi.org/10.1016/j.jchf.2023.03.017
Vancouver
Arnold SV, Silverman DN, Gosch K, Nassif ME, Infeld M, Litwin S, et al. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. 2023;11(8):893-900. doi:10.1016/j.jchf.2023.03.017
BibTeX
@article{Arnold2023,
author = {Arnold, Suzanne V and Silverman, Daniel N and Gosch, Kensey and Nassif, Michael E and Infeld, Margaret and Litwin, Sheldon and Meyer, Markus and Fendler, Timothy J},
title = {Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction},
journal = {JACC: Heart Failure},
year = {2023},
volume = {11},
number = {8},
pages = {893--900},
doi = {10.1016/j.jchf.2023.03.017}
}
EUVIMED